Literature DB >> 8092930

Modifications of liver bile acids pool during modulation of rat hepatocarcinogenesis by phenobarbital and nafenopin.

N M Delzenne1, H S Taper, M Roberfroid.   

Abstract

As previously demonstrated, chronic administration of phenobarbital (0.05% in the drinking water) and of nafenopin (0.1% in the diet) increases the incidence and the kinetics of appearance of liver cancers. If bile acids play a key role in liver carcinogenesis, it might thus be expected that treatments like phenobarbital or nafenopin, which positively modulate that process, also modify their hepatic pool. The aim of the present study was to analyze the modifications of the liver bile acid pool during the modulation of liver carcinogenesis by phenobarbital and nafenopin. The animals were submitted to the hepatocarcinogenic initiation-selection (IS) procedure adapted from Solt and Farber. As compared to basal diet, the chronic feeding of phenobarbital significantly increased the total concentrations of liver bile acids both at weeks 9 and 17. That increase was mainly due to a change in the concentration of beta-muricholic acid and hyodeoxycholic acid and, to a lesser extent, of chenodeoxycholic acid and alpha-muricholic acid. In contrast, feeding a diet containing nafenopin led to a significant decrease in the concentration of liver bile acids, due to a complete disappearance of chenodeoxycholic acid and muricholic acid, and a decrease in the concentration of hyodeoxycholic acid. Carcinomas appearing in IS phenobarbital-treated rats contain fewer bile acids than the surrounding parenchyma (because of the decrease in deoxycholic acid and ursodeoxycholic acid) whereas the malignant tumors appearing in IS nafenopin-treated rats have essentially the same pattern of bile acids as the surrounding parenchyma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092930     DOI: 10.1007/s002040050087

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  13 in total

Review 1.  Modulation of hepatocarcinogenesis.

Authors:  M B Roberfroid; N Delzenne; V Préat
Journal:  Annu Rev Pharmacol Toxicol       Date:  1991       Impact factor: 13.820

2.  Determination of bile acids in needle biopsies of human liver.

Authors:  H Greim; P Czygan; F Schaffner; H Popper
Journal:  Biochem Med       Date:  1973-10

Review 3.  Hydroxylations in biosynthesis and metabolism of bile acids.

Authors:  I Björkhem; H Danielsson
Journal:  Mol Cell Biochem       Date:  1974-09-30       Impact factor: 3.396

4.  Bile acid synthesis in rat liver peroxisomes: metabolism of 26-hydroxycholesterol to 3 beta-hydroxy-5-cholenoic acid.

Authors:  S K Krisans; S L Thompson; L A Pena; E Kok; N B Javitt
Journal:  J Lipid Res       Date:  1985-11       Impact factor: 5.922

5.  Stimulation of cholesterol 7 -hydroxylase by phenobarbital in two strains of rats.

Authors:  S Shefer; S Hauser; E H Mosbach
Journal:  J Lipid Res       Date:  1972-01       Impact factor: 5.922

6.  Effect of the hypolipidemic drug nafenopin (2-methyl-2-(p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy)propionic acid; TPIA; SU-13,437), on the hepatic disposition of foreign compounds in the rat.

Authors:  W G Levine
Journal:  Drug Metab Dispos       Date:  1974 Mar-Apr       Impact factor: 3.922

7.  Primate biliary physiology. 8. The effect of phenobarbital upon bile salt synthesis and pool size, biliary lipid secretion, and bile composition.

Authors:  R N Redinger; D M Small
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

8.  Effects of the peroxisome proliferator di(2-ethylhexyl)phthalate on enzymes in rat liver and on carcinogen-induced liver altered foci in comparison to the promoter phenobarbital.

Authors:  H Maruyama; T Tanaka; G M Williams
Journal:  Toxicol Pathol       Date:  1990       Impact factor: 1.902

9.  Comparative analysis of the effect of phenobarbital, dichlorodiphenyltrichloroethane, butylated hydroxytoluene and nafenopin on rat hepatocarcinogenesis.

Authors:  V Préat; J de Gerlache; M Lans; H Taper; M Roberfroid
Journal:  Carcinogenesis       Date:  1986-06       Impact factor: 4.944

10.  Absence of a promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide.

Authors:  S Numoto; H Mori; K Furuya; W G Levine; G M Williams
Journal:  Toxicol Appl Pharmacol       Date:  1985-01       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.